Neonc Technologies Holdings, Inc. (NTHI) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Calabasas, CA, 미국. 현재 CEO는 Amir Farrokh Heshmatpour.
NTHI 을(를) 보유 IPO 날짜 2025-03-26, 8 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $103.17M.
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
